Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025CancersOpen Access

Metformin Beyond Diabetes: A Precision Gerotherapeutic and Immunometabolic Adjuvant for Aging and Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

ARAbdul RehmanSSShakta Mani SatyamMEMohamed El‐Tanani

Discussion

Loading...

Member takes

Overview

This review reveals how metformin improves cancer outcomes and behavioral aging in various populations, highlighting its potential as an immunometabolic intervention.

Key Points

  • Metformin shows promise by impacting cancer incidence and improving outcomes in immunotherapy.
  • Clinical data highlight its ability to reduce multimorbidity and reverse biological age markers effectively.
  • The review synthesizes findings from landmark trials, emphasizing metformin's role in age-related disease trajectories.
  • Future directions include personalized approaches and combination therapies to optimize metformin's impact on aging and cancer.

Cite This Study

Rehman et al. (2025) studied this question.

synapsesocial.com/papers/68c23f1fb210217d64795dddhttps://doi.org/10.3390/cancers17152466
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Repurposing Metformin in Precision Oncology: Mechanistic Insights, Biomarker-Guided Strategies, and Translational Imperatives2025
  2. 2Editorial: Emerging horizons of metformin: exploring recent advances and addressing challenges in research and clinical utilization2025
  3. 3A Review of Metformin's Anti-aging Mechanisms2025
  4. 4Repurposing Metformin: An Update On Mechanism And Exploring Therapeutic Horizons2025
  5. 5Metformin: A revolutionary drug that halts the aging process, keeping you youthful indefinitely2025